Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals CoSZSE:301201 +2.26%75 Net Margin % is 5.46% as of Mar. 2026, which is 70% below its 10-year median of 18.37. GuruFocus rates SZSE:301201 with a GF Score™ of 75/100 and a GF Value™ of ¥30.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 962 Drug Manufacturers companies, Chengda Pharmaceuticals Co ranks worse than 67.26% on this metric.
The historical rank and industry rank for Chengda Pharmaceuticals Co's Net Margin % or its related term are showing as below:
SZSE:301201'
s Net Margin % Range Over the Past 10 Years
Min: -8.44 Med: 18.37 Max: 32.48
Current: -0.77
SZSE:301201's Net Margin % is ranked worse than 67.26% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SZSE:301201: -0.77
Chengda Pharmaceuticals Co (SZSE:301201) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Chengda Pharmaceuticals Co Net Margin % Related Terms
Chengda Pharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a Net Margin % of 5.46% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Chengda Pharmaceuticals Co and its competitors. This is 70% below median its historical median of 18.37. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #647 out of 962 companies in the Drug Manufacturers industry, placing it in the top 67.3%.
Is Chengda Pharmaceuticals Co's Net Margin % too high?
Chengda Pharmaceuticals Co's current Net Margin % of 5.46% is 70% below median its 10-year median of 18.37. The Drug Manufacturers industry median Net Margin % is 5.56. Chengda Pharmaceuticals Co's value of 5.46% is 1.8% below this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #647 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #647 out of 962 companies for Net Margin %. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median Net Margin % is 5.56. Chengda Pharmaceuticals Co's value of 5.46% is 1.8% below this benchmark. While the company's 10-year median is 18.37 vs. the industry median of 5.56, Chengda Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current Net Margin % of 5.46% is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current Net Margin % is 5.46%, which is 70% below median its own 10-year median of 18.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥37.94 — trading 24.6% above its estimated fair value. The current Net Margin % is 5.46%, which is 70% below median its 10-year median of 18.37 and 1.8% below the Drug Manufacturers industry median of 5.56. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Net Margin % is 5.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥37.94 is trading 24.6% above its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SZSE:301201:
Net Margin %: 5.46% (70% below median its 10-year median of 18.37)
GF Value™: ¥30.45 vs. price of ¥37.94 (24.6% above fair value)
Industry Position: 1.8% below the Drug Manufacturers median (#647 of 962)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score
Get the complete analysis for SZSE:301201
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
